Abstract: In an in vitro diagnostic test for osteoarthritis or rheumatoid arthritis, the amount or presence in a sample of anisomerised or optically inverted protein fragment is measured which derives from perlecan, bigylcan, decorin, fibrillin-1 or protocadherin or which is a specific sequence from aggrecan, type II collagen, COMP or CILP.
Type:
Grant
Filed:
May 22, 2002
Date of Patent:
December 15, 2009
Assignee:
Nordic Bioscience Diagnostics A/S
Inventors:
Stephan Christgau, Dennis B. Henriksen, Paul A. C. Cloos